Ser9
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser9  -  PARK2 (mouse)

Site Information
IVFVRFNsSYGFPVE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 11096954

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:
COLO-205 (intestinal) ( 1 ) , HCT116 (intestinal) ( 1 ) , HEK293T (epithelial) ( 1 ) , HeLa (cervical) ( 1 ) , HT-29 (intestinal) ( 1 ) , MEF (fibroblast) ( 1 )

Upstream Regulation
Putative in vivo kinases:
AMPKA1 (human) ( 1 )
Kinases, in vitro:
AMPKA1 (human) ( 1 )
Treatments:
A769662 ( 1 ) , cycloheximide ( 1 ) , metformin ( 1 ) , TNF ( 1 ) , Z-VAD-FMK ( 1 )

Downstream Regulation
Effects of modification on PARK2:
intracellular localization ( 1 ) , molecular association, regulation ( 1 ) , phosphorylation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 1 ) , signaling pathway regulation ( 1 )
Induce interaction with:
RIPK3 (human) ( 1 )

References 

1

Lee SB, et al. (2019) The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome. Nat Cell Biol 21, 940-951
31358971   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.